• They see the world through this, we see our goal through them

  • A unique Pharmaceutical Company

    Orphan Europe, part of the Recordati group, is a unique pharmaceutical company focusing on the research and development of orphan medicinal products. Since 1990 we have used big thinking and extensive know-how on behalf of people affected by rare diseases. Patients and their families are central to our planning, our thinking and our actions. Recordati orphan drugs is present in the USA through its company Recordati Rare Diseases.

  • Big thinking for people with rare diseases

    Everything we do is driven by the needs of people who have a rare disease

  • Patients and families

    Orphan Europe is committed to establishing strong alliances with patients and patient organisations worldwide, to achieve the common goal of building knowledge and awareness, improving diagnosis, access to treatment and prevention of rare diseases.

  • Collaboration

    At Orphan Europe, we're committed to improving the diagnosis and management of rare diseases.

  • Current products and pipeline

    Orphan Europe is a leading pharmaceutical company dedicated to the development of orphan medicinal products.

  • Our responsibilities

    As part of our commitment to rare diseases, Orphan Europe has partnered and supports various programmes and activities

  • Recordati Rare Diseases Foundation

    Advancing knowledge in rare diseases: independent, professional education and training

  • Partnering with Orphan Europe

    Orphan Europe has developed successful partnerships with a number of well-established pharmaceutical and biotechnology companies and research institutes.

  • Pharmacovigilance at Orphan Europe

    aims to enhance patient care and patient safety in relation to the use of our drugs. We support public health programs by providing reliable, balanced information for the effective assessment of the risk-benefit profile of medicines.

News and events

Orphan Europe is pleased to invite the scientific community to participate in a symposium entitled Screening for treatable diseases in newborns and children: “the earlier the better” next September the 29th in Brussels (Belgium)

Orphan Europe is pleased to participate in the 17th International Pediatric Nephrology Association (IPNA) Congress, organized from the 20th to the 24th September in Iguaçu (Brazil).

The SSIEM Congress will gather physicians from all over the world with the aim to foster the study of inherited metabolic disorders, and to improve the networking between clinicians, laboratory scientists and basic researchers.

More than ever before, Orphan Europe is involved in the care of preterm babies affected by Patent Ductus Arteriosus.

About us

Corporate Brochure,